Gilteritinib

Gilteritinib

Saved in:

Bibliographic Details
Main Authors:	Harini Raghunathan, Parathan Karunakaran
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd.
Series:	Indian Journal of Medical and Paediatric Oncology
Subjects:	FLT3 mutation relapsed/refractory AML TKI gilteritinib
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1809991
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
by: Chun-xiao Hou, et al.
Published: (2024-12-01)

Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation
by: Chen Liang, et al.
Published: (2025-12-01)

Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner
by: Tianzhuo Zhang, et al.
Published: (2025-04-01)

Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
by: Qi Zhou, et al.
Published: (2025-02-01)

FLT3: A narrative review
by: Nikhil M Kumar, et al.
Published: (2025-01-01)

FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context
by: Suvir Singh, et al.
Published: (2024-04-01)

Recurrent Hyperbilirubinemia with Midostaurin during Consolidation in a Patient of AML with FLT3 Mutation and Review of Literature for Alternative Maintenance Strategy
by: Deepak Kumar Shukla, et al.
Published: (2025-08-01)

A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice
by: Monica Messina, et al.
Published: (2024-12-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
by: Dipesh Dave, et al.

FREQUENCY OF FMS-LIKE TYROSINE KINASE 3 KINASE DOMAIN POINT MUTATION (FLT3/TKD MUTATION) IN DIFFERENT AGE GROUPS OF ACUTE MYELOID LEUKEMIA PATIENTS.
by: Khaleeq unnisa, et al.
Published: (2014-08-01)

Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis
by: Jingmei Yang, et al.
Published: (2025-03-01)

GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS
by: Mehmet Hilmi DOGU, et al.
Published: (2023-04-01)

LOW DOSE CYTARABINE PLUS SORAFENIB IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA
by: Tural Mahmudov
Published: (2025-07-01)

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers
by: Yongchang Tang, et al.
Published: (2025-01-01)

CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?
by: Pilar Lloret-Madrid, et al.
Published: (2025-05-01)

A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML
by: Noor Rashidha Binte Meera Sahib, et al.
Published: (2024-11-01)

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML
by: Brian J. Ball, et al.
Published: (2025-07-01)

Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations
by: Bhavana Bhatnagar, et al.
Published: (2025-04-01)

Decursin induces FLT3-ITD acute myeloid leukemia cell apoptosis by increasing the expression of the ubiquitin-conjugase UBE2L6
by: Tianxin Zhang, et al.
Published: (2025-04-01)

SPECTRUM AND IMMUNOPHENOTYPIC PROFILE OF ACUTE LEUKEMIA: A TERTIARY CENTER FLOW CYTOMETRY EXPERIENCE
by: Nishit Gupta, et al.
Published: (2019-02-01)

Relapse-specific genetic patterns in the exomic mutational landscape in acute myeloid leukemia
by: Wardah Qureshi, et al.
Published: (2025-03-01)

Characterization of the FLT3 Mutation in Newly Diagnosed Patients with Acute Myeloid Leukemia
by: Luay Fahad, et al.
Published: (2024-06-01)

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia
by: Tessa S. Seale, et al.
Published: (2025-05-01)

The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX‐351) in Acute Myeloid Leukemia Patients: A Systematic Review
by: Abdulwahab M. Alzahrani, et al.
Published: (2025-05-01)

Clinical outcomes and relapse patterns in pediatric acute leukemia patients undergoing hematopoietic cell transplantation: a multicenter Brazilian experience
by: Polliany Roberta Dorini Pelegrina, et al.
Published: (2025-03-01)

CEBPA mutation in acute myeloid leukemia: prognostic impact of bZIP domain mutation
by: Roy Raj, et al.
Published: (2024-10-01)

The Novel Diketopiperazine Derivative, Compound 5-3, Selectively Inhibited the Proliferation of FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Cells
by: Shijie Bi, et al.
Published: (2025-07-01)

Management of isolated recurrence of extramedullary myeloid tumor at a single site
by: Muddu Vamshi Krishna, et al.
Published: (2013-01-01)

Sweet syndrome induced by FLT3 inhibitors: case report and literature review
by: Linhui Yang, et al.
Published: (2024-12-01)

Analysis of relapsed/refractory Hodgkin lymphoma treated with autologous transplantation: A single-center experience
by: Vishal Kulkarni, et al.
Published: (2020-01-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Молекулярная диагностика мутаций гена FLT3 у пациентов с острыми миелоидными лейкозами
by: Е. К. Зайкова, et al.
Published: (2020-04-01)

Survival Outcomes in EGFR‐Mutant Non‐Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages
by: Haoran Qi, et al.
Published: (2025-05-01)

Feasible and Rapid Screening of <i>IDH1/2</i> and <i>FLT3-TKD2</i> Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia
by: José Vicente Gil, et al.
Published: (2025-05-01)

Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations
by: Jie Yang, et al.
Published: (2025-09-01)

Targeted therapy of newly diagnosed <i>FLT3</i>-mutated acute myeloid leukemia. A single-center ambispective cohort study
by: N. K. Pastukhov, et al.
Published: (2025-03-01)

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation
by: Zhonghui Jiang, et al.
Published: (2025-08-01)

Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity
by: Chenchen Zhao, et al.
Published: (2025-02-01)

Development and preclinical characterization of AMG 329: a human antibody neutralizing FLT3 ligand
by: Annie Lau-Kilby, et al.
Published: (2025-12-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)